M&A / Deals Lilly bets up to $800M for BioArctic’s brain delivery tech BioSpaceEli Lilly plans to use BioArctic's technology to shuttle an undisclosed drug candidate into the brain.NeuroscienceRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) BioSpace Eli Lilly plans to use BioArctic’s technology to shuttle an undisclosed drug candidate into the brain. Neuroscience Read full story Post navigation Previous: Boehringer advances duo for aggressive cancers into phase 3Next: AbbVie climbs post-Allergan M&A peak with Apogee buy Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
